Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXN OTCMKTS:AYRWF OTCMKTS:CUBTD NASDAQ:TNFA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$6.09-6.6%$6.72$5.41▼$12.05$8.03M1.484,161 shs1,756 shsAYRWFAyr Wellness$0.02+4.3%$0.01$0.00▼$0.26$1.92M1.63174,858 shs1,248 shsCUBTDCurative Biotechnology$1.10$1.10$0.03▼$2.24$7.50M1.312,679 shsN/ATNFATNF Pharmaceuticals$3.99-0.7%$3.94$0.04▼$8.94$7.37M2.0432.22 million shs538,354 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-0.99%-1.63%-14.18%-6.31%-29.81%AYRWFAyr Wellness+4.27%-14.07%+16.33%-0.58%-90.09%CUBTDCurative Biotechnology0.00%0.00%0.00%+7.84%-28.80%TNFATNF Pharmaceuticals-0.75%-1.97%-4.55%+7.84%-71.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$6.09-6.6%$6.72$5.41▼$12.05$8.03M1.484,161 shs1,756 shsAYRWFAyr Wellness$0.02+4.3%$0.01$0.00▼$0.26$1.92M1.63174,858 shs1,248 shsCUBTDCurative Biotechnology$1.10$1.10$0.03▼$2.24$7.50M1.312,679 shsN/ATNFATNF Pharmaceuticals$3.99-0.7%$3.94$0.04▼$8.94$7.37M2.0432.22 million shs538,354 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-0.99%-1.63%-14.18%-6.31%-29.81%AYRWFAyr Wellness+4.27%-14.07%+16.33%-0.58%-90.09%CUBTDCurative Biotechnology0.00%0.00%0.00%+7.84%-28.80%TNFATNF Pharmaceuticals-0.75%-1.97%-4.55%+7.84%-71.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 1.00SellN/AN/AAYRWFAyr Wellness 0.00N/AN/AN/ACUBTDCurative Biotechnology 0.00N/AN/AN/ATNFATNF Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest AYRWF, ADXN, CUBTD, and TNFA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2026ADXNAddex Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$210K35.66N/AN/A$4.67 per share1.30AYRWFAyr Wellness$463.63M0.00N/AN/A$3.14 per share0.01CUBTDCurative BiotechnologyN/AN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/A$286.76 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics-$8.12M-$5.74N/AN/AN/AN/A-105.98%-87.61%6/25/2026 (Estimated)AYRWFAyr Wellness-$359.31M-$2.67N/AN/AN/AN/AN/AN/AN/ACUBTDCurative BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/AN/ATNFATNF Pharmaceuticals-$23.36M-$231.00N/AN/AN/AN/A-69.21%-33.98%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AAYRWFAyr WellnessN/AN/AN/AN/AN/ACUBTDCurative BiotechnologyN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A1.401.40AYRWFAyr WellnessN/AN/AN/ACUBTDCurative BiotechnologyN/AN/AN/ATNFATNF PharmaceuticalsN/A0.930.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%AYRWFAyr Wellness0.91%CUBTDCurative BiotechnologyN/ATNFATNF Pharmaceuticals9.64%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%AYRWFAyr Wellness8.10%CUBTDCurative BiotechnologyN/ATNFATNF Pharmaceuticals0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.23 million1.05 millionNot OptionableAYRWFAyr Wellness2,440116.77 million107.32 millionNot OptionableCUBTDCurative Biotechnology46.82 millionN/ANot OptionableTNFATNF Pharmaceuticals61.85 million1.84 millionN/AAYRWF, ADXN, CUBTD, and TNFA HeadlinesRecent News About These CompaniesTNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open TodayJune 23 at 2:38 PM | businesswire.comTnf Pharmaceuticals: A Corporate Pivot Under ScrutinyFebruary 24, 2026 | newscase.comNWhy did QCLS stock surge over 60% today?December 4, 2025 | msn.comRheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsightNovember 5, 2025 | finance.yahoo.comForward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling InhibitorOctober 30, 2025 | markets.businessinsider.comQ/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"September 26, 2025 | tmcnet.comTNF Pharmaceuticals changes name to Q/C TechnologiesSeptember 25, 2025 | msn.comTNF Pharmaceuticals stock soars after strategic pivot to quantum computingSeptember 25, 2025 | investing.comTNF Pharmaceuticals regains compliance with NasdaqSeptember 17, 2025 | msn.comTNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 17, 2025 | businesswire.comTNF Pharmaceuticals Announces Closing of $7 Million Private PlacementSeptember 4, 2025 | businesswire.comTNF Pharmaceuticals stock climbs after securing exclusive crypto computing rightsSeptember 2, 2025 | investing.comPharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency ApplicationsSeptember 2, 2025 | businesswire.comTNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing ComplianceAugust 29, 2025 | finance.yahoo.comTNF Pharmaceuticals announces improved financial positionAugust 20, 2025 | msn.comTNF Pharmaceuticals Strengthens Financial Position for Growth and Value CreationAugust 19, 2025 | businesswire.comTNF Pharmaceuticals Inc Ordinary Shares TNFA - MorningstarJuly 11, 2025 | morningstar.comMAkers files written objection to her Judicial Investigative admonishmentJuly 4, 2025 | wvgazettemail.comWDorothy Marillyn AkersJuly 2, 2025 | chattanoogan.comCNewly-signed running back Cam Akers has already changed his jersey numberJune 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAYRWF, ADXN, CUBTD, and TNFA Company DescriptionsAddex Therapeutics NASDAQ:ADXN$6.09 -0.43 (-6.61%) Closing price 06/23/2026 01:39 PM EasternExtended Trading$6.41 +0.32 (+5.34%) As of 06:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Ayr Wellness OTCMKTS:AYRWF$0.02 +0.00 (+4.27%) As of 06/23/2026 02:30 PM EasternAyr Wellness Inc. operates as a vertically-integrated multi-state cannabis operator that cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. It owns and operates a chain of cannabis retail stores under AYR, Liberty Health Sciences, and The Dispensary brand names. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.Curative Biotechnology OTCMKTS:CUBTD$1.10 0.00 (0.00%) As of 06/22/2026Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.TNF Pharmaceuticals NASDAQ:TNFA$3.99 -0.03 (-0.75%) As of 06/22/2026TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning Why nVent Could Be a Long-Term AI Infrastructure Winner These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
